A Tale Of Two Gene Therapy Biotechs: Freeline Divests As Kriya Invests

 
• By Ayisha Sharma

Freeline Therapeutics and Kriya are taking divergent paths to success amid market doldrums, as the former divests and pulls back on investment, while the latter bulks up its pipeline through an acquisition.  

Road splitting off into two
Freeline And Kriya Are Taking Different Paths • Source: Shutterstock

More from Business

More from Scrip